All Updates

All Updates

icon
Filter
Partnerships
Tavros Therapeutics partners with Vividion Therapeutics to discover oncology targets
Precision Medicine
Oct 13, 2022
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Product updates
Partnerships
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
Precision Medicine

Precision Medicine

Oct 13, 2022

Tavros Therapeutics partners with Vividion Therapeutics to discover oncology targets

Partnerships

  • Precision oncology company Tavros Therapeutics agreed to a five-year partnership with biopharmaceutical company Vividion Therapeutics to explore four potential oncology targets using Tavros’s functional genomics discovery platform.

  • Under the terms of the partnership, Tavros received USD 17.5 million in an upfront cash payment. Additionally, Tavros is eligible to receive up to USD 430.5 million in preclinical, clinical, and commercial milestone payments as well as low-single-digit royalties on sales on potential programs. Vividion also has the option to develop five more targets with up to USD 482 million in future payments. 

  • Founded in 2020, Tavros Therapeutics aims to match biomarkers with drug combinations using its functional genomics discovery platform. It has several undisclosed drug targets in the pipeline that are focused on small-molecule inhibitors. 

  • Independently operated Vividion Therapeutics is a fully owned subsidiary of big pharma Bayer AG through acquisition in 2021. The company develops new drug candidates using its proprietary chemoproteomic platform to treat patients with cancer and immune diseases. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.